OnKure Therapeutics (OKUR) Share-based Compensation (2020 - 2026)
OnKure Therapeutics' (OKUR) quarterly Share-based Compensation came in at $2.8 million in Q1 2026, up 1.28% YoY from $2.7 million in Q1 2025, and down 7.92% on a QoQ basis from $3.0 million in Q4 2025.
OnKure Therapeutics (OKUR) Share-based Compensation (2020 - 2026) Analysis & Trends
OnKure Therapeutics (OKUR) has 7 years of Share-based Compensation data on file, last reported at $2.8 million in Q1 2026.
- Quarterly Share-based Compensation rose 1.28% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.7 million (up 62.78% YoY) and the FY2025 annual result came in at $11.6 million, up 156.8% from the prior year.
- Share-based Compensation slipped to $2.8 million in Q1 2026, from $3.0 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $3.0 million in Q4 2025 to a low of -$3.6 million in Q4 2023.
- A 5-year average of $840117.6 and a median of $282000.0 in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation sank 298.8% — and 2023, when it jumped 19183.33%.
- Tracing OKUR's Share-based Compensation over 5 years: stood at -$2.8 million in 2022, then declined by 27.22% to -$3.6 million in 2023, then jumped by 170.48% to $2.5 million in 2024, then increased by 19.19% to $3.0 million in 2025, then retreated by 7.92% to $2.8 million in 2026.
- The last three Share-based Compensation figures came in at $2.8 million (Q1 2026), $3.0 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | OnKure Therapeutics | 195.74 Mn | 19.35 Mn | - | 3.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.05 Mn |
| Jun 30, 2026 | 3.05 Mn |
| Mar 31, 2026 | 2.78 Mn |
| Mar 31, 2026 | 2.78 Mn |
| Dec 31, 2025 | 3.02 Mn |
| Dec 31, 2025 | 3.02 Mn |
| Sep 30, 2025 | 2.96 Mn |
| Sep 30, 2025 | 2.96 Mn |
| Jun 30, 2025 | 2.91 Mn |
| Jun 30, 2025 | 2.91 Mn |
| Mar 31, 2025 | 2.75 Mn |
| Mar 31, 2025 | 2.75 Mn |
| Dec 31, 2024 | 2.53 Mn |
| Dec 31, 2024 | 2.53 Mn |
| Sep 30, 2024 | 77,000.00 |
| Sep 30, 2024 | 77,000.00 |
| Jun 30, 2024 | 1.81 Mn |
| Jun 30, 2024 | 1.81 Mn |
| Mar 31, 2024 | 107,000.00 |
| Mar 31, 2024 | 107,000.00 |